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Pieter Jelle Vissera,e, José Luis Molinuevof,g, Frans R.J. Verheya and Bengt Winbladb
aDepartment of Psychiatry and Neuropsychology, Alzheimer Centre Limburg, School for Mental Health and
Neurosciences, Maastricht University, Maastricht, The Netherlands
bDepartment of Neurobiology, Care Science and Society, Center for Alzheimer Research, Division
of Neurogeriatrics, Karolinska Institute, Huddinge, Sweden
cDepartment of NeuroGeriatrics, University Duisburg-Essen, Essen, Germany
dDepartment of Neurology, University Medical Center Ljubljana, Ljubljana, Slovenia
eDepartment of Neurology and Alzheimer Centre, VU University Medical Centre, Amsterdam, The Netherlands
f Alzheimer Disease and Other Cognitive Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain
gBarcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain
Handling Associate Editor: Sophie Vandepitte
Accepted 17 August 2017
Abstract.
Background: Diagnostic research criteria for Alzheimer’s disease support the use of biomarkers in the cerebrospinal fluid
(CSF) to improve the accuracy of the prognosis regarding progression to dementia for people with mild cognitive impairment
(MCI).
Objective: The aim of this study was to estimate the potential incremental cost-effectiveness ratio of adding CSF biomarker
testing to the standard diagnostic workup to determine the prognosis for patients with MCI.
Methods: In an early technology assessment, a mathematical simulation model was built, using available evidence on added
prognostic value as well as expert opinion to estimate the incremental costs and quality-adjusted life years (QALYs) of 20,000
virtual MCI patients with (intervention strategy) and without (control strategy) relying on CSF, from a health-care sector
perspective and with a 5-year time horizon.
Results: Adding the CSF test improved the accuracy of prognosis by 11%. This resulted in an average QALY gain of 0.046
and D 432 additional costs per patient, representing an incremental cost-effectiveness ratio of D 9,416.
Conclusion: The results show the potential of CSF biomarkers in current practice from a health-economics perspective. This
result was, however, marked by a high degree of uncertainty, and empirical research is required into the impact of a prognosis
on worrying, false-positive/negative prognosis, and stigmatization.
Keywords: Alzheimer’s disease, cerebrospinal fluid, cost-utility, economic evaluation, mild cognitive impairment, prognosis,
risk
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INTRODUCTION
With a global prevalence of 47 million [1] and a
corresponding economic impact of US$ 818 billion
[2], dementia imposes a substantial burden on soci-
eties worldwide. Limited national care budgets force
governments and health insurers to reimburse only
a selection of all available healthcare technologies.
These choices are ideally based on cost-effectiveness
evidence, such that the available budget is spent on the
selection of interventions that result in the maximum
societal health gain.
Clinical guidelines for suspected Alzheimer’s dis-
ease (AD) recommend a standard assessment of
clinical history, cognition, behavioral symptoms,
co-morbidities, and neuroimaging in patients with
suspected dementia [3]. In the last decade, propos-
als for new research-based diagnostic criteria for AD
have been developed, including advanced diagnos-
tic technologies that enable the early identification of
brain abnormalities [4–7]. As regards CSF biomark-
ers, the evidence base for these recommendations
is formed by studies of diagnostic and prognostic
accuracy [8].
Diagnostic tests are, however, no exception to
any other health intervention [9, 10]; because they
consume part of the health care budget means that
this part cannot be spent on an alternative inter-
vention and its corresponding opportunity to gain
health. To support reimbursement by governments or
health insurers, diagnostic tests should therefore be
evaluated in terms of incremental cost-effectiveness
using clinical or quality-adjusted life year (QALY)
outcomes. This allows intervention effects to be
compared between different diseases, as reflected
by different outcomes, to enable a well-informed
decision to be made about reimbursement.
A few studies have attempted to reflect the clini-
cal utility of CSF biomarkers by assessing the impact
on diagnostic decision making [11, 12] or diagnostic
confidence [13] of adding CSF biomarkers to stan-
dard clinical tests. The results were mixed, and the
studies did not report on health effects. A systematic
review on the effect of early identification of AD hall-
marks did not find any empirical evidence of health
benefits derived from persons with and without iden-
tified AD-related brain abnormalities in pre-dementia
[14]. Nevertheless, this and other reviews reported on
the potential benefits and harms of early [14] and
genetic testing [15] or a timely diagnosis [15] of
AD or other neurodegenerative disorders [16]. This
includes benefits related to decreased anxiety if the
cause is found not to be AD, management of cognitive
symptoms to reduce the related burden, and planning
for future care and personal adjustments to prevent
burden or crisis situations when symptoms increase.
Potential harms include the impact of stigmatization,
anxiety and depression after a diagnosis is communi-
cated (whether true or false), and the side-effects of
the lumbar puncture, such as headache. In the absence
of a registered treatment, no benefits can be expected
in terms of slowing down the disease progression in
the pre-dementia stage of AD.
Previous studies on the cost-effectiveness of using
CSF markers have either disregarded any potential
health impact [17] or assumed a hypothetical disease-
modifying treatment [18–22] to be decided upon
based on CSF test results. Such results only reflect
a limited part of the potential impact of CSF testing.
The lack of empirical evidence on health effects
related to CSF testing limits the appraisal of this
technology to support reimbursement decisions. Fur-
ther advancement of the health-economic assessment
of CSF requires identifying the topics for future
empirical research. This could be done in an early
technology assessment [23], which could identify
drivers of uncertainty as well as assess the sensi-
tivity of health-economic outcomes to different sets
of assumptions on parameters for which evidence
is lacking. Such early assessment could also deter-
mine the potential of CSF tests, which, if it proves
to be substantial, would argue for supporting further
empirical research into input parameters for which
little evidence is available. Finally, it could aid in the
development of a simulation framework that reflects
clinical practice and aggregates the pieces of evidence
from various sources. The aim of this study was to
estimate the potential incremental cost-effectiveness
ratio of adding CSF biomarker testing to the stan-
dard diagnostic workup to determine the prognosis
for patients with MCI. An early technology assess-
ment was performed by means of a simulation study
using existing evidence as well as plausible assump-
tions on potential health benefits and harms, without
evaluating any hypothetical treatment.
MATERIALS AND METHODS
The potential cost-effectiveness of CSF was esti-
mated using a decision model that simulates the
diagnostic test workup in usual care to establish a
prognosis for progression to dementia (by means of
predictive values using a logistic regression model)
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and comparing this with a simulation of a situation
in which CSF biomarkers are added to the usual-
care diagnostic test workup to establish a prognosis
for progression to dementia (using the same logistic
regression model but with CSF biomarkers added).
This was done for a group of virtual patients who
visit a memory clinic for the first time and have been
diagnosed with MCI. The model estimates the incre-
mental costs and effects for a strategy in which the
prognosis is based on the diagnostic workup rec-
ommended for usual care and a strategy in which
the prognosis is based on adding a CSF test to the
diagnostic workup recommended for usual care. No
treatment effects were reflected in the model because
currently none are recommended for MCI. The Sup-
plementary Material describes in detail the model
structure, data analysis, consistency, and results. The
model code is available on http://www.smard.org or
upon request to the corresponding author.
In the domain of public health, a progression to
any-type dementia can be considered more important
than identifying the cause of this progression as being
AD, vascular disease, or other. Hence, we focused on
the prognosis for progression to any-type dementia
rather than the diagnosis of its sub-types. Never-
theless, since the underlying cause is required to
determine the prognosis, this study partly represents
the value of using CSF biomarkers for diagnosing the
underlying pathology.
Model structure
The simulation started by creating a virtual group
of individual MCI patients and their characteris-
tics of age, gender, level of education, underlying
neurodegenerative disease (present or absent), CSF
biomarker values (amyloid-1-42, total tau, and
phosphorylated tau), cognition, memory, and medial
temporal atrophy on MRI. For each patient, the
following events were simulated: 1) a prognosis
consisting of a probability of developing any-type
dementia; 2) one or more follow-up visits to a mem-
ory clinic for a clinical evaluation; 3) progression
to dementia; and 4) death. Simulated effects also
included the impact of the prognosis in terms of
reduced worrying and stigmatization, the impact of a
false-positive/negative prognosis, and the impact of
lumbar puncture side-effects on health-related quality
of life (HrQOL). Simulated costs included the visits
to the clinic, lumbar puncture, and costs related to
MCI and dementia. See Fig. 1 for a simple overview
of the model structure.
The model was based on various assumptions, such
as: 1) a patient with no neurodegenerative disease
will never develop dementia; 2) a patient with a neu-
rodegenerative disease will develop dementia within
the model’s time frame of 5 years; 3) dementia is
irreversible; and 4) the probability of dementia pro-
gression corresponds to the dementia prognosis and
degree of certainty communicated to a patient. A full
list of assumptions can be found in the Supplementary
Material §2.4.
Control and intervention strategy
The model simulated a control strategy, which
reflected the effects of a prognosis of progression to
dementia over a 5-year period using the standard test
workup [3], and an intervention strategy, in which
CSF biomarker results are added to this workup. The
prognosis was established using a prediction model
[24] based on demographic information and results
from tests on cognition, depression, and neuroimag-
ing, and a prediction model adding CSF test outcomes
to the first prediction model.
Preparatory data analyses
Both the characteristics of the virtual patients at
their initial visit and their risk of progression to
dementia were simulated using the results of a study
by Handels et al. [24] based on set of merged data
from different cohort studies.
The decision model simulated 20,000 virtual
patients and their characteristics using random draws
from the study participants’ distribution and correla-
tion structure. Table 1 represents the characteristics
of the merged dataset and of the characteristics of the
simulated virtual patients based on the averages and
distributions of the patients in the merged dataset.
Each virtual patient’s prognosis was simulated by
applying a dementia progression prediction model
[24] to the characteristics of the 20,000 simulated
patients. A prognosis was a predicted probability of
progression to dementia. Two prognoses were sim-
ulated: one representing the control strategy (using
all test information except CSF biomarkers) and one
representing the intervention strategy (using all test
information including CSF biomarkers).
Regular follow-up visits were simulated if the
prognosis (i.e., predicted probability of progression
to dementia) was positive (i.e., a predicted probabil-
ity ≥0.50) or uncertain. Clinical experts considered
a prognosis uncertain if the probability was higher
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Fig. 1. Basic model structure (abbreviations: CSF, cerebrospinal fluid; FN, false-negative prognosis; FP, false-positive prognosis; HrQOL,
health-related quality of life; MRI MTA, medial temporal lobe atrophy on magnetic resonance imaging; NDD, neurodegenerative disorder;
TN, true-negative prognosis; TP, true-positive prognosis; QALY, quality-adjusted life year).
Table 1
The observed baseline characteristics of 250 participants in the cohort studies analyzed by Handels et al.
[24] and the simulated baseline characteristics of the 20,000 patients entering the decision model
Characteristic Original study Simulated cohort
Mean (SD) or n (%) Range Mean (SD) or n (%) Range
Age 68.6 (7.5) 52.0 to 89.0 68.7 (8.1) 35.2 to 101.8
Female gender 111 (44%) NA 45% NA
Education, y 11.2 (3.1) 4 to 18 11.2 (3.2) –2 to 24
MMSE 26.9 (2.4) 18 to 30 27.0 (2.4) 12 to 30
WLT delayed recall z-score –1.6 (1.2) –5.6 to 2.3 –1.6 (1.2) –6.2 to 3.7
Depression1 0.3 (0.6) 0 to 2 0.3 (0.5) 0 to 4
MRI MTA left and right 2.3 (1.8) 0 to 6 2.2 (1.7) 0 to 6
CSF A 666 (296) 157 to 1538 661 (268) 37 to 1666
CSF t-tau 446 (237) 52 to 1179 457 (262) 0 to 1396
CSF p-tau 71 (30) 16 to 172 69 (14) 25 to 133
Progression to dementia (events) 99 (40%) NA 25% NA
Table partly copied from Handels et al. [24] with permission of the author. 10 = no symptoms, 1 = mild symp-
toms, 2 = moderate symptoms. CSF, cerebrospinal fluid; MMSE, Mini-Mental State Examination; MRI, magnetic
resonance imaging; MTA, medial temporal lobe atrophy; WLT, word learning test; SD, standard deviation.
than 0.24, and on average recommended to follow up
patients every 9.3 months for a maximum of 5 years.
Patients with a low probability of decline (<0.24)
were sent home. If the test result was false-negative,
they returned to the clinic 1 year after progression to
dementia occurred.
The following aspects were assumed to influ-
ence the HrQOL of each simulated patient: MCI
syndrome, worrying about progression to dementia,
false-positive prognosis, false-negative prognosis,
stigmatization, and lumbar puncture adverse effects.
These effects were expressed in terms of a utility, a
number ranging from 0 (reflecting the worst possi-
ble health state or death) to 1 (reflecting a perfect
health state). Each simulated patient was assumed
to worry about their possible progression to demen-
tia before having visited a medical professional. The
clinical experts in our study estimated that worrying
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Fig. 2. Overview of the assumed impact of reduced worrying, false-positive/negative prognosis, stigma and lumbar puncture side-effects on
a patient’s utility. FN, false-negative prognosis; FP, false-positive prognosis; TN, true-negative prognosis; TP, true-positive prognosis; LP,
lumbar puncture.
represents a utility decrease of 0.23. This effect was
assumed to reflect maximum uncertainty at a prog-
nostic dementia probability of 0.50. After testing,
a specific prognosis was established for the patient.
This prognosis was assumed to correspond linearly
to a decreased disutility relating to worrying about
dementia. For example, a prognosis of 0.95 reflects
a high certainty of progression to dementia, result-
ing in a reduction of worrying about progression to
dementia and thus an increase in utility (see left top
Fig. 2, red dashed).
However, this positive prognosis also corresponds
to a stigmatizing effect of being labelled as high
probability of progression to dementia, resulting in
a decrease of utility. The clinical experts estimated
this as a 0.26 utility decrease, and it was assumed
to correspond linearly to the prognostic dementia
probability (0.26 at a probability of 1 or when diag-
nosed with dementia, and 0 at a probability of 0.50;
see Fig. 2, yellow dashed). The clinical experts esti-
mated the utility decrease due to a false-positive
prognosis (probability of progression to dementia
between 0.50 and 1 whereas progression to dementia
does actually not takes place within 5 years) and a
false-negative prognosis (probability of progression
to dementia between 0 and 0.50 whereas progres-
sion to dementia actually takes place within 5 years)
at 0.36 and 0.19, respectively. These effects were
also assumed to correspond linearly to the proba-
bility (see Fig. 2, blue dashed). The clinical experts
estimated various impacts of side-effects of a lum-
bar puncture. These were combined with evidence on
the probability of occurrence and duration [25] (see
Table 2). Details on the method of obtaining expert
opinion are included in the Supplementary Material
(§3.2.12). Utility scores were linearly interpolated
between events to estimate QALYs.
Costs related to MCI and dementia as well as
for a clinical visit and the lumbar puncture were
obtained from various Swedish sources [26, 27] (see
Table 2), reflecting a health-care sector perspective.
Prices were converted to Euro 2015 estimates.
Outcomes
The primary outcome was the average incremental
net monetary benefit of the intervention strategy over
a period of 5 years. This net monetary benefit was
calculated by valuing 1 QALY at D 20,000 [28] and
subtracting the costs from it. A positive incremental
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Table 2
Model input parameters (2015 price estimates)
Category Parameter Parameter estimate for individual
Patient characteristics age, gender, education, MMSE, word
learning test, depression, MRI MTA, A,
t-tau, p-tau
See Supplementary Material §3.2.1
Prognostic probability logistic regression prediction model
LP related Headache Bootstrap sampling: none: p = 0.91; mild:
p = 0.06; moderate: p = 0.03
Headache duration (in days) Bootstrap sampling: 0.5 (p = 0.26); 1.5
(p = 0.24); 3 (p = 0.28); 7 (p = 0.22)
Serious complication p = 0.01
Serious complication duration (years) 1.1/52
Decisions Cut-off probability uncertain prognoses 0.24
Follow-up duration (years) 5
Time to event (years) Regular follow-up visit 9.3/12
Patient with underdiagnosed NDD revisits
the clinic
1.0
Re-establish prognosis 5
Progression to dementia Beta distribution:  = 1.09;  = 2.19
Death Sampling from survival table
HrQOL utilities MCI 0.72
Dementia 0.63
Worrying –0.23
Stigma of NDD –0.26
Impact of FP –0.36
Impact of FN –0.19
LP mild headache –0.10
LP moderate headache –0.16
LP serious complication –0.22
Costs Base visit 1210
(D , 2015) Regular follow-up visit 787
Lumbar puncture 621
Annual care MCI 3524
Annual care mild dementia 10219
CBS, Statistics Netherlands; EP, expert opinion; FN, false-negative prognosis; FP, false-positive prognosis; HrQOL, health-
related quality of life; k, shape parameter; LP, lumbar puncture; MCI, mild cognitive impairment; MMSE, Mini-Mental
State Examination; MRI, magnetic resonance imaging; MTA, medial temporal atrophy; NDD, neurodegenerative disorder;
NM, not modelled; p, probability; pc, percentile; p-tau, phosphorylated tau; SE, standard error; t-tau, total tau; , shape
parameter; , shape parameter; θ, scale parameter.
net monetary benefit reflects the preferred situation
of a health gain in terms of QALY improvement at
reasonable costs or cost savings (or cost savings at
a reasonable QALY loss). Secondary outcomes were
total incremental costs, incremental QALYs (1 QALY
reflects one year in full HrQOL), concordance index
(reflecting the accuracy of the prognosis) and the
proportion correctly reclassified.
Sensitivity analysis
The clinical expert opinions, the empirical evi-
dence and the various assumptions made in this
simulation study were subject to a degree of uncer-
tainty, which resulted in uncertainty in the estimated
costs and QALYs. In a probabilistic sensitivity anal-
ysis, parameter uncertainty was assessed by running
the model 10,000 times, each time using a different
set of plausible input values by randomly drawing
them from their parameter distributions (see Table 2)
(see Supplementary Material §3.4 for details).
RESULTS
Main outcomes
The simulated sample of 20,000 virtual patients
had an average age of 69 years, 45% were female,
and they had an average MMSE of 27.0 and a 5-year
prevalence of progression to dementia of 25% (see
Table 1). In 46% the risk of progression to dementia
between before and after using CSF tests was 0.10
or more (on a scale from 0 to 1). In this subsam-
ple, 68% of the risk changes was correct (meaning
an increased risk over time and actually progressing
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to dementia, or a decreased risk over time and not
actually progressing to dementia). The concordance
index was 0.705 for the control strategy and 0.801 for
the intervention strategy.
The intervention strategy resulted in more positive
prognoses (14% versus 10% in the control strat-
egy), more false-negative prognoses (5% versus 4%
in the control strategy), fewer false-positive prog-
noses (16% versus 20% in the control strategy), and
more follow-up visits (on average 2.04 visits per
patient versus 1.80 visits in the control strategy) with
corresponding impact on QALYs and costs.
The simulation estimated a 0.046 mean QALY
gain and D 432 mean additional costs per patient
when adding the lumbar puncture to the usual-care
diagnostic workup for the prognosis of progression
to dementia in MCI. This resulted in an incre-
mental cost-effectiveness ratio of D 9,416. Assuming
a willingness-to-pay of D 20,000 per QALY, the
incremental net monetary benefit was D 486.
Uncertainty
These outcomes were subject to uncertainty. The
incremental cost-effectiveness plane in Fig. 3 reflects
how the uncertainty of most input parameters in
the model (e.g., expert opinions and risk prediction
coefficients) resulted in uncertainty in the costs and
QALY outcomes. Of the plausible scenarios, 95%
had incremental costs of between D –767 and D 1,165,
incremental QALYs of between –0.145 and 0.314 and
incremental net monetary benefit of between D –3,829
and D 6,440.
Scenarios with a negative net monetary benefit
are unwanted. These are reflected by the red-shaded
area in Fig. 3; the blue dots in the left top quad-
rant (33% of all plausible scenarios), indicating an
HrQOL loss at higher costs; and the blue dots in
the right top quadrant above the willingness-to-pay
threshold of D 20,000 per QALY (12%), indicating
the unwanted situation of improved QALY but at
unacceptably high costs. Sixteen percent of all plau-
sible scenarios resulted in the preferred outcome of
improved QALY and cost savings, and 40% led to
improved QALY outcomes at acceptable costs below
the willingness-to-pay threshold (reflected by the
green-shaded area in Fig. 3). Less than 1% fell in the
lower left quadrant, indicating a QALY loss at lower
costs. Assuming a willingness-to-pay of D 20,000
for a gain of 1 QALY, 56% of all plausible scenar-
ios were cost-effective. In other words, there was
a 56% chance that adding the lumbar puncture to
Fig. 3. Incremental cost-effectiveness plane. Each blue dots rep-
resents the average incremental costs and average incremental
QALYs for 5,000 simulated patients in the control strategy and
intervention strategy, using 10,000 different sets of random param-
eter draws from a plausible distribution, reflecting parameter
uncertainty. The red dots represent 5,000 simulated patients in
the deterministic mode reflecting stochastic uncertainty. The black
open circle and cross represent the average incremental costs and
effects of the deterministic and probabilistic results, respectively.
The green shaded area to the right of the dashed line represents
scenarios cost-effective at a willingness-to-pay of D 20,000 per
incremental QALY; the red shaded area to the left of the dashed
line represents scenarios that are not cost-effective.
Fig. 4. Incremental cost-effectiveness acceptability curve repre-
senting the probability of CSF being cost-effective at various levels
of willingness to pay for 1 QALY.
the usual-care diagnostic workup would result in
cost-effective care. Assuming a willingness-to-pay
of D 80,000 per QALY, this was 64% (see Fig. 4).
In other words, 64% of the plausible scenarios were
cost-effective (implicates 36% were not).
The univariate sensitivity analysis showed the
impact of various specific plausible scenarios on the
cost-effectiveness of adding CSF testing. The costs of
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the lumbar puncture, the impact of stigma, the impact
of reduced worrying, the impact of a false-negative
prognosis, and the cut-off value at which the proba-
bility that a person will be followed up had the highest
impact on the cost-effectiveness outcomes (see Sup-
plementary Material §5.2). For example, a higher
assumed impact of a false-negative prognosis by the
clinical experts resulted in a lower incremental net
monetary benefit, because the intervention strategy
resulted in more false-negative prognoses (5% ver-
sus 4% in the control strategy). Since the intervention
strategy resulted in fewer false-positive prognoses
(16% versus 20% in the control strategy), its rela-
tion with incremental monetary benefit was opposite
for the impact of a false-positive compared to the
impact of a false-negative. Similarly, since more pos-
itive prognoses occurred in the intervention group
(14% versus 10% in the control strategy), a higher
stigmatizing effect resulted in a lower incremental
net monetary benefit. The uncertainty about the com-
plications of a lumbar puncture and the impact and
duration of headache had almost no impact on the
cost-effectiveness.
Omitting the specific uncertainty from the beta
estimates of the logistic regression prediction model
resulted in 74% and 91% of all plausible scenar-
ios being cost-effective at a willingness-to-pay of
D 20,000 and D 80,000 per QALY, respectively (see
Supplementary Material §5.2).
DISCUSSION
Determining CSF biomarkers in addition to the
usual-care diagnostic workup to establish the prog-
nosis for progression to dementia resulted in an
average potential gain of 0.046 QALYs at D 432
additional costs. This corresponds to a poten-
tial cost-effectiveness ratio of D 9,416 per QALY.
These estimates were, however, highly uncertain,
because even assuming a willingness-to-pay of
D 80,000 per QALY gained, the likelihood that
adding CSF biomarkers is cost-effective was only
64%, corresponding to a 36% likelihood that
it is not.
This early technology assessment reflected the
potential value of CSF testing in the pre-dementia
state, in which no treatment is available, by estimat-
ing plausible impacts of reduced worrying, stigma
and false-positive and false-negative prognosis. The
health-economic outcomes show that on average the
benefits could outweigh the harms, thus indicating
the potential of CSF testing for prognostic purposes.
However, the uncertainty in the results was consider-
able and makes it difficult to draw strong conclusions
for the purpose of reimbursement by governments
or health insurers. Nevertheless, our study yielded
various useful insights.
The model showed the combined impact of adding
CSF biomarkers to the usual-care diagnostic workup.
The cost-effectiveness estimate can be seen as a set of
trade-offs. For example, the investment in perform-
ing a lumbar puncture reduced the costs of following
up patients. Another example is that a gain in QALYs
due to reduced worrying because of a correct positive
prognosis as a result of the lumbar puncture came at
the cost of a loss of QALYs due to the stigmatizing
effect of the positive prognosis. These set of trade-
offs indicate the importance of a holistic viewpoint
and moving forward from the typical assumption that
improved prognostic or diagnostic accuracy in terms
of sensitivity and specificity reflects clinical utility.
Despite the positive cost-effectiveness outcome of
this study, the QALY gain of 0.046 was small, rep-
resenting an average quality-of-life improvement of
0.009 (on a scale of 0 representing death and 1 repre-
senting full quality of life) for a duration of 5 years,
as mortality did not differ between the control and
intervention strategies.
Comparison with other studies
There have been other studies evaluating the incre-
mental cost-effectiveness of using CSF biomarkers.
The majority of these studies [18–22] used a hypo-
thetical future scenario in which disease-modifying
treatment is available that significantly reduces the
rate of progression. Such studies have evaluated the
impact of using a CSF test on decision making
for treatment, and showed that this was poten-
tially cost-effective. A study by Valcárcel-Nazco
et al. [17] evaluated CSF biomarkers for deci-
sions about off-label Donepezil treatment in MCI.
They showed lower costs per correctly diagnosed
patient when using CSF biomarkers (D 1,336) versus
using standard clinical diagnostic criteria (D 3,167),
on the assumption that this off-label treatment is
both effective and reduces costs in MCI. Potential
non-medical impacts such as reduced worrying, false-
positive/negative prognosis and stigmatization were
not assessed, as the study disregarded HrQOL. Our
study is the first to attempt to assess the value of CSF
testing in actual current clinical practice in terms of
HrQOL and costs.
R.L.H. Handels et al. / Cost-Utility CSF for Prognosis in MCI 1485
Recommendations
We recommend empirical research into the param-
eters to which the health-economic outcomes were
most sensitive. These included the impact of stigma,
the impact of reduced worrying and the impact of a
false-negative prognosis. Uncertainty caused by the
uncertain costs of performing a lumbar puncture and
the uncertain costs of performing a follow-up visit
could be solved by applying the fixed price from the
specific hospital in which the CSF technology is to
be implemented. The uncertainty in the cut-off value
to decide about following up patients should be the
topic of an optimization analysis, as this can gener-
ate the optimal cut-off value to ensure cost-effective
application of CSF testing in practice. Furthermore,
our results indicated that the evidence base on side
effects due to CSF assessment is sufficiently large.
Uncertainty due to the logistic regression prediction
model was probably overestimated, as data from other
studies have been collected in other studies but were
not requested by us.
The model framework supported the concept of
including potential health effects for the evaluation
of a diagnostic test. Although the discrete event sim-
ulation increased the level of complexity compared
to the well-established Markov model, it allowed
the inclusion of various levels of uncertainty with-
out losing detail due to categorizing them into states
[24]. If health effects do indeed occur within the rel-
atively short time period of 5 years, a trial-based
economic evaluation could serve as an alternative,
though involving a risk of bias if there is no option
of blinding for undergoing a lumbar puncture and
for interpreting the test result. Nevertheless, a model
framework has the potential to identify subgroups for
whom cost-effectiveness is high [29].
Limitations
The simulation model is a simplistic representation
of the real-world situation. Actual current practice is
more complex and heterogeneous, especially in terms
of the medical decisions made with or without rely-
ing on biomarkers and between positive, negative or
intermediate test outcomes, which were not taken into
account in our study. Furthermore, the way a proba-
bility or risk is communicated to and received by a
person most likely varies considerably. Discounting
was disregarded, as insufficient resources were avail-
able to build this into the model. Discounting would
likely lower the cost-effectiveness, as costs occurred
at the start, while savings due to reduced follow-
ups and effects occurred later in time, although the
impact is likely to be low, due to the relatively short
time period. By adopting a health-care sector per-
spective, we omitted out-of-pocket expenses such as
travel costs, informal caregiving time, and productiv-
ity losses, factors for which it is difficult to indicate
whether they would have led to over- or underesti-
mation of the cost-effectiveness. The results of this
study are therefore mainly useful to estimate the
potential of CSF testing for scientific purposes, rather
than to advise upon clinical management in practice
or policy. These limitations were of secondary rele-
vance to the exploratory nature of this study, to show
the balance regarding the non-medical impact of
testing. Nevertheless, our extensive sensitivity anal-
ysis covered a wide range of plausible inputs and
methodological choices made, making their impact
on results transparent (see Supplementary Material
§6 for details).
Expressing health effects of diagnostic information
in terms of QALYs might be challenging. Scales like
the ICECAP provide an index of capabilities [30],
which could be more sensitive to the effects of diag-
nostic information, and constitute an alternative to
EQ5D-based utility scores.
Conclusions
Adding CSF tests to the usual-care diagnostic
workup for the prognosis of progression to dementia
in persons with MCI was cost-effective when rely-
ing on expert opinion about its expected impact in
current practice. This result was, however, highly
uncertain and calls for empirical research into the
impact of a prognosis on the aspect of reducing worry-
ing, false-positive and false-negative prognosis, and
stigmatization.
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